Patient-derived ovarian cancer organoid carries immune microenvironment and bloodvessel keeping high response to cisplatin

Sep 21, 2026

Uploaded by Ezra

Ovarian cancer remains a high-recurrence and high-mortality malignancy, with High-Grade Serous Ovarian Cancer (HGSOC) as the most common aggressive subtype. A rare HGSOC organoid model is reported that includes both the patient immune microenvironment and blood vessels even in their absence. The organoids derived from patient samples preserve histological and molecular heterogeneity while maintaining CD34+ endothelial cells. Whole exome sequencing reveals key mutations including CSMD3, TP53, and GABRA6, and organoids show cisplatin sensitivity, supporting testing for patients resistant to carboplatin and paclitaxel. Integration of immune microenvironment and vasculature supports future immunotherapy and anti-angiogenic strategies.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages14

Reading Time35 min

AccessFree to download

Introduction

Background and unmet needs in HGSOC

Current first-line therapy and limitations

Platinum resistance and alternative options

Rationale for personalized organoid-based strategies

DOI: 10.1002/mco2.697 ORIGINAL ARTICLE Patient-derived ovarian cancer organoid carries immune microenvironment and bloodvessel keeping high response to cisplatin Yuqing Zhao1 ,\# Yanghua Shi2 Xinxin Han2, 5 ,∗ Chen Wang2 ,\# Wei Deng3,4 ,\# Lanyang Li2 ,\# Jiping Liu2 Xiang Tao1 Jian Zhang2 Qi Cao1 ,∗ Chunhui Cai2 ,∗ 1 Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China 2 Department of Research, Shanghai LiSheng Biotech, Shanghai, China 3 LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China 4 Department of Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 5 Organ Regeneration X Lab, LiSheng East China Institute of Biotechnology, Peking University, Jiangsu, China ∗ Correspondence Xinxin Han, Organ Regeneration X Lab, LiSheng East China Institute of Biotechnology, Peking University, Jiangsu 226299, China. [Email:](Email: xxhan@sibs.ac.cn)[ xxhan@sibs.ac.cn](Email: xxhan@sibs.ac.cn) Chunhui Cai, Department of Research, Shanghai LiSheng Biotech, Shanghai, China. Email: [caichunhui@lishengbiotech.com](caichunhui@lishengbiotech.com) [Qi Cao](Qi Cao), [Obstetrics & Gynecology Hospital](Obstetrics & Gynecology Hospital), Fudan University, Shanghai, China. [Email:](Email: qicao@fudan.edu.cn)[ qicao@fudan.edu.cn](Email: qicao@fudan.edu.cn) Funding information National Natural Science Foundation of China, Grant/Award Numbers: 82374506, 32200581 Abstract Ovarian cancer is high recurrence and mortality malignant tumor. The most common ovarian cancer was High-Grade Serous Ovarian Cancer. However, High-Grade Serous Ovarian Cancer organoid is rare, which organoid with patient immune microenvironment and blood vessels even absence. Here, wereport a novel High-Grade Serous Ovarian Cancer organoid system derived from patient ovarian cancer samples. These organoids recapitulate High-Grade Serous Ovarian Cancer organoids’ histological and molecular heterogeneity while preserving the critical immune microenvironment and blood vessels, as evidenced by the presence of CD34+ endothelial cells. Whole exome sequencing identifies key mutations (CSMD3, TP53, GABRA6) . Organoids show promise in testing cisplatin sensitivity for patients resistant to carboplatin and paclitaxel, with notable responses in cancer proteoglycans and p53 ( TP53) signaling, like ACTG/ACTB1/AKT2 genes and BBC3/MDM2/PERP. Integration of immune microenvironment and blood vessels enhances potential for novel therapies like immunotherapies and angiogenesis inhibitors. Our work may provide anew detection system and theoretical basis for ovarian cancer research and individual therapy. \#Yuqing Zhao, Chen Wang, Wei Deng and Lanyang Li contributed equally to this work. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. MedComm. 2024;5:e697 . [https://doi.org/10.1002/mco2.697](https://doi.org/10.1002/mco2.697) [wileyonlinelibrary.com/journal/mco2](wileyonlinelibrary.com/journal/mco2) 1 of 14 ZHAO et al. KEYWORDS cisplatin, organoid, ovarian cancer, tumor microenvironment (TME), vascularization 1 INTRODUCTION Ovarian cancer, a complex and multifaceted disease, remains a formidable challenge in oncology, with HighGrade Serous Ovarian Cancer (HGSOC) being the most aggressive and prevalent form.1,2 Despite advances in detection and treatment, HGSOC is characterized by high recurrence, incidence, and mortality rates that underscore the urgent need for more effective therapeutic strategies.3–5 The 5-year relative survival rate for all types of ovarian cancer is approximately 50%, with significant variation depending on fa

FAQs

What problem does the study address in HGSOC treatment?

HGSOC has high recurrence and mortality, and most patients eventually develop platinum resistance, limiting the effectiveness of current one-size-fits-all therapies.

How are the patient-derived ovarian cancer organoids characterized?

The organoids preserve histological and molecular heterogeneity and maintain a critical immune microenvironment and blood vessels, including CD34+ endothelial cells.

Why is cisplatin response a key focus of the organoid system?

Organoids are used to test cisplatin sensitivity, showing potential utility for patients resistant to carboplatin and paclitaxel, with observed pathway and gene-related responses.

Sep 21, 2026

Uploaded by Ezra